Graphite Bio hands Nasdaq spot to presbyopia biotech Lenz Therapeutics as PhIII readouts loom
Presbyopia drug developer Lenz Therapeutics will take Graphite’s place and will have enough funding to take it all the way to commercialization, should its lead eye drop candidate get FDA approval, the companies said Wednesday morning. They expect the deal to close in the first quarter of next year, at which point Lenz would start its public life as $LENZ.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.